# A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk

> **NCT06930573** · PHASE4 · RECRUITING · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 30 (estimated)

## Conditions studied

- HCC

## Interventions

- **DRUG:** AK112

## Key facts

- **NCT ID:** NCT06930573
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-04
- **Primary completion:** 2026-05-24
- **Final completion:** 2027-12-24
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06930573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06930573, "A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06930573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*